financetom
Business
financetom
/
Business
/
Cloudflare Insider Sold Shares Worth $17,557,834, According to a Recent SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Cloudflare Insider Sold Shares Worth $17,557,834, According to a Recent SEC Filing
Jun 18, 2026 3:51 PM

06:02 PM EDT, 06/18/2026 (MT Newswires) -- Michelle Zatlyn, Director, President and Board Co-Chair, on June 16, 2026, sold 76,923 shares in Cloudflare ( NET ) for $17,557,834. Following the Form 4 filing with the SEC, Zatlyn has control over a total of 427,847 Class A common shares of the company, with 360,807 shares held directly and 67,040 controlled indirectly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1477333/000178695126000010/xslF345X05/wk-form4_1781819885.xml

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Tech firm Mercury Systems Q1 profit beats expectations on strong demand 
Tech firm Mercury Systems Q1 profit beats expectations on strong demand 
Nov 4, 2025
Overview * Mercury Systems ( MRCY ) fiscal Q1 rev grows 10.2% yr/yr, beating analyst expectations * Adjusted EPS for fiscal Q1 beats consensus, improving significantly year-over-year * Company announced $200 mln share repurchase program, reflecting confidence in future prospects Outlook * Mercury Systems ( MRCY ) did not provide specific future revenue or EPS guidance in the statement Result...
Day One Biopharmaceuticals Q3 revenue beats estimates on OJEMDA strength
Day One Biopharmaceuticals Q3 revenue beats estimates on OJEMDA strength
Nov 4, 2025
Overview * Day One Q3 revenue of $39.8 mln beats analyst expectations * OJEMDA net product revenue rises 15% from Q2, driven by higher patient demand * Company raises full-year 2025 OJEMDA revenue guidance to $145-$150 mln Outlook * Company raises OJEMDA full-year 2025 revenue guidance to $145-$150 mln Result Drivers * INCREASED DEMAND - OJEMDA net product revenue rose...
Soleno Therapeutics posts Q3 profit on strong VYKAT XR sales 
Soleno Therapeutics posts Q3 profit on strong VYKAT XR sales 
Nov 4, 2025
Overview * Soleno Q3 net income at $26 mln, achieving profitability with VYKAT XR sales * VYKAT XR sales reach $66 mln in Q3, more than doubling from previous quarter * Company raised $230 mln through stock offering, strengthening financial position Outlook * Soleno expects selling, general and administrative expenses to rise post-VYKAT XR commercialization Result Drivers * VYKAT XR...
Mirum Pharmaceuticals Q3 revenue rises on LIVMARLI sales growth
Mirum Pharmaceuticals Q3 revenue rises on LIVMARLI sales growth
Nov 4, 2025
Overview * Mirum Pharmaceuticals Q3 2025 revenue rises 47% yr/yr to $133 mln * Net income for Q3 2025 at $2.9 mln, a turnaround from loss last year * Mirum updates 2025 revenue guidance to $500-$510 mln Outlook * Mirum updates 2025 revenue guidance to $500-$510 mln * Company expects VISTAS study topline data in Q2 2026 * Mirum anticipates...
Copyright 2023-2026 - www.financetom.com All Rights Reserved